COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal

Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth.

Zacks Investment Research • Feb 19, 2026

Cencora's animal health unit to merge with Covetrus in $3.5 billion deal

Drug distributor Cencora will merge its MWI Animal Health unit with privately held Covetrus in a deal that values MWI at $3.5 billion, the companies said on Wednesday.

Reuters • Feb 18, 2026

Covetrus and MWI Animal Health to Merge

CONSHOHOCKEN, Pa. & PORTLAND, Maine--(BUSINESS WIRE)--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform. “Our mission has always been to empower veterinary practices to work smarter and deliver better care,” said Ben Wolin, President and Chief Executive O.

Business Wire • Feb 18, 2026

Is the Options Market Predicting a Spike in Cencora Stock?

Investors need to pay close attention to COR stock based on the movements in the options market lately.

Zacks Investment Research • Feb 17, 2026

Cencora Closes $3.0 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Se.

Business Wire • Feb 13, 2026

Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February.

Business Wire • Feb 10, 2026

Cencora beats quarterly profit estimates on strong demand for specialty medicines

Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies.

Reuters • Feb 4, 2026

Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript

Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript

Seeking Alpha • Feb 4, 2026

Cencora Reports Fiscal 2026 First Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,.

Business Wire • Feb 4, 2026

Cencora (COR) Q1 Earnings Top Estimates

Cencora (COR) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $4.07 per share. This compares to earnings of $3.73 per share a year ago.

Zacks Investment Research • Feb 4, 2026